조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 조사년월 : 2023년07월
RNA 분석 시장 : 제품(시약, 장비, 소프트웨어, 서비스), 기술(PCR, 시퀀싱, 마이크로어레이, RNA 간섭), 용도(창약, 임상 진단), 최종 사용자(제약, 생명공학, CRO), 지역별 – 2028년까지의 세계 예측
RNA Analysis Market by Product (Reagents, Instruments, Software, Services), Technology (PCR, Sequencing, Microarrays, RNA Interference), Application (Drug Discovery, Clinical Diagnostics), End User (Pharma, Biotech, CROs), Region – Global Forecast to 2028
| 페이지 수 | 257 |
| 도표 수 | 224 |
| 구성 | 영문조사보고서 |
| 가격 |
The global RNA analysis market size is projected to reach USD 9.9 billion by 2028 from 5.3 billion in 2023, at a CAGR of 13.4% during the forecast period. Factors such as the advancements in the field of transcriptomics studies, and the rising demand for reagents used in RNA analysis due to increased transcriptomics studies supporting the growth of therapeutics are driving the demand for RNA analysis products & services.
“The reagents/consumables segment accounted for the highest growth rate in the RNA analysis market, by product & service, during the forecast period”
In 2022, the reagents/consumables segment accounted for the highest growth rate. The product & service market is segmented into reagents/consumables, instruments, services, and software. Expanding applications of peptides in therapeutics, drug design, and gene synthesis and the growing number of ongoing research projects involving RNA analysis contributes to the segment’s prominence in the RNA analysis market.
“Asia Pacific region is likely to grow at a faster pace.”
The RNA analysis market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of the RNA analysis market. The large share of the region is attributable to various factors such as the presence of leading players in the region paired with the continuing research activities of developing new genomic therapies. Asia Pacific region is likely to grow at a faster pace owing to various factors such as rising government initiatives for generic medicines in the region, and the emergence of new market players in the RNA analysis market.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side – 30%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bio-Rad Laboratories, Inc. (US)
• Illumina, Inc. (US)
• Eurofins Scientific (Luxembourg)
• Agilent Technologies, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• Promega Corporation (US)
• QIAGEN N.V. (Germany)
• Standard BioTools (US)
• Sequentia Biotech SL (Spain)
• Acobiom (France)
• GenXPro GmbH (Germany)
• CD Genomics (US)
• Promega Corporation (US)
• Lexogen GmbH (Austria)
• Cenix BioScience GmbH (Germany)
• Takara Holdings, Inc. (Japan)
• bioMérieux SA (France)
• LC Sciences LLC (US)
• Oxford Nanopore Technologies (UK)
• Zymo Research Corporation (US)
• GeneDx (US)
• Partek Incorporated (US)
• BGI Group (China)
Research Coverage:
This report provides a detailed picture of the RNA analysis market. It aims at estimating the size and future growth potential of the market across different segments, such the product, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall RNA analysis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Growing demand for personalized medicine, Rising pharmaceutical and biotechnology R&D expenditure and government funding, and the Increasing applications of RNA sequencing in transcriptomics), restraints (High capital investments), opportunities (High growth opportunities in emerging markets, Increasing applications in toxicogenomics, Increasing focus on biomarker discovery, Rising focus on outsourcing), and challenges (Data management in transcriptomics research, Lack of effective bioinformatics tools, Dearth of skilled professionals.)
• Product & Service Development/Innovation: Detailed insights on newly launched products/services, and technological assessment of the RNA analysis market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the RNA analysis market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the RNA analysis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of leading players like Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Eurofins Scientific (Luxembourg), and among others in the RNA analysis market.
목차
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY 30
1.5 LIMITATIONS 30
1.6 STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 31
1.7.1 RECESSION IMPACT 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 33
2.1.2 PRIMARY DATA 34
FIGURE 2 RNA ANALYSIS MARKET: BREAKDOWN OF PRIMARIES 34
2.2 MARKET SIZE ESTIMATION 35
FIGURE 3 RNA ANALYSIS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022) 35
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 36
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 36
2.2.1 INSIGHTS FROM PRIMARIES 37
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 37
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, TECHNOLOGY, APPLICATION, AND END USER) 38
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 38
2.3 GROWTH RATE ASSUMPTIONS 39
FIGURE 8 RNA ANALYSIS MARKET: CAGR PROJECTIONS, 2023–2028 39
FIGURE 9 RNA ANALYSIS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 40
FIGURE 10 DATA TRIANGULATION METHODOLOGY 41
2.5 STUDY ASSUMPTIONS 42
2.6 RISK ANALYSIS 42
2.7 IMPACT OF ECONOMIC RECESSION ON RNA ANALYSIS MARKET 42
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH) 43
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 43
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 43
3 EXECUTIVE SUMMARY 44
FIGURE 11 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 44
FIGURE 12 RNA ANALYSIS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 45
FIGURE 13 RNA ANALYSIS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46
FIGURE 14 RNA ANALYSIS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47
FIGURE 15 GEOGRAPHICAL SNAPSHOT: RNA ANALYSIS MARKET 48
4 PREMIUM INSIGHTS 50
4.1 RNA ANALYSIS MARKET OVERVIEW 50
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 50
4.2 NORTH AMERICA: RNA ANALYSIS MARKET SHARE, BY APPLICATION & COUNTRY (2022) 51
FIGURE 17 DRUG DISCOVERY APPLICATIONS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA ANALYSIS MARKET IN 2022 51
4.3 RNA ANALYSIS MARKET SHARE, BY END USER, 2022 52
FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 52
4.4 RNA ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN RNA ANALYSIS MARKET FROM 2023 TO 2028 53
4.5 RNA ANALYSIS MARKET, BY REGION (2023–2028) 54
FIGURE 20 NORTH AMERICA TO CONTINUE TO DOMINATE RNA ANALYSIS
MARKET UNTIL 2028 54
4.6 RNA ANALYSIS MARKET: DEVELOPED VS. EMERGING ECONOMIES 55
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 22 MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
TABLE 4 RNA ANALYSIS MARKET: IMPACT ANALYSIS 57
5.2.1 DRIVERS 57
5.2.1.1 Growing demand for personalized medicine 57
FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2022 58
5.2.1.2 Rising pharmaceutical and biotechnology R&D expenditure and government funding 59
FIGURE 24 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 60
5.2.1.3 Increasing applications of RNA sequencing in transcriptomics 60
5.2.2 RESTRAINTS 61
5.2.2.1 High capital investments 61
5.2.3 OPPORTUNITIES 61
5.2.3.1 High growth opportunities in emerging markets 61
5.2.3.2 Increasing applications in toxicogenomics 62
5.2.3.3 Increasing focus on biomarker discovery 63
5.2.3.4 Rising focus on outsourcing 63
5.2.4 CHALLENGES 63
5.2.4.1 Data management in transcriptomics research 63
5.2.4.2 Lack of effective bioinformatics tools 64
5.2.4.3 Dearth of skilled professionals 64
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 65
5.4 VALUE CHAIN ANALYSIS 66
FIGURE 25 VALUE CHAIN ANALYSIS OF RNA ANALYSIS MARKET: RESEARCH AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 66
5.5 SUPPLY CHAIN ANALYSIS 67
FIGURE 26 RNA ANALYSIS MARKET: SUPPLY CHAIN ANALYSIS 68
5.6 ECOSYSTEM ANALYSIS 68
TABLE 5 SUPPLY CHAIN ECOSYSTEM 69
5.7 PATENT ANALYSIS 70
FIGURE 27 PATENT APPLICATIONS FOR RNA ANALYSIS MARKET, JUNE 2012–JUNE 2023 70
5.8 LIST OF MAJOR PATENTS 71
5.9 TECHNOLOGY ANALYSIS 72
TABLE 6 COMPARISON OF MODERN RNA ANALYSIS METHODS 73
5.10 PORTER’S FIVE FORCES ANALYSIS 73
TABLE 7 RNA ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 73
5.10.1 THREAT OF NEW ENTRANTS 74
5.10.2 THREAT OF SUBSTITUTES 74
5.10.3 BARGAINING POWER OF SUPPLIERS 74
5.10.4 BARGAINING POWER OF BUYERS 74
5.10.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 74
5.11 REGULATORY ANALYSIS 75
5.11.1 REGULATIONS FOR RNA ANALYSIS PRODUCTS 75
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.12 KEY CONFERENCES AND EVENTS IN 2023 78
TABLE 11 RNA ANALYSIS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023 78
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 79
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA ANALYSIS PRODUCTS 79
5.13.2 BUYING CRITERIA 80
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 80
6 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE 81
6.1 INTRODUCTION 82
TABLE 12 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 82
6.2 REAGENTS/CONSUMABLES 82
6.2.1 REAGENTS/CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD 82
TABLE 13 RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY REGION,
2021–2028 (USD MILLION) 84
TABLE 14 NORTH AMERICA: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET,
BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 15 EUROPE: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 16 ASIA PACIFIC: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
6.3 INSTRUMENTS 86
6.3.1 GROWING NEED FOR ACCURATE ANALYSIS TO DRIVE ADOPTION OF AUTOMATED INSTRUMENTS 86
TABLE 17 RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 18 NORTH AMERICA: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 19 EUROPE: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 20 ASIA PACIFIC: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
6.4 SOFTWARE 89
6.4.1 GROWING NEED FOR DATA MANAGEMENT AND QUALITY ENHANCEMENTS TO DRIVE DEMAND FOR SOFTWARE SOLUTIONS 89
TABLE 21 RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 22 NORTH AMERICA: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 23 EUROPE: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 24 ASIA PACIFIC: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
6.5 SERVICES 92
6.5.1 INCREASING OUTSOURCING OF SERVICES TO PROPEL MARKET GROWTH 92
TABLE 25 RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 26 NORTH AMERICA: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 27 EUROPE: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 28 ASIA PACIFIC: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
7 RNA ANALYSIS MARKET, BY TECHNOLOGY 95
7.1 INTRODUCTION 96
TABLE 29 RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 96
7.2 POLYMERASE CHAIN REACTION 96
7.2.1 ABILITY OF REAL-TIME PCR TO AID IN QUANTIFICATION OF LOW-COPY TRANSCRIPTS TO BOOST DEMAND 96
TABLE 30 RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 31 NORTH AMERICA: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 32 EUROPE: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 33 ASIA PACIFIC: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.3 SEQUENCING 99
7.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES TO AID MARKET GROWTH 99
TABLE 34 RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 35 NORTH AMERICA: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 36 EUROPE: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 37 ASIA PACIFIC: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 102
7.4 MICROARRAYS 103
7.4.1 WIDE ADOPTION OF MICROARRAYS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH 103
TABLE 38 RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 39 NORTH AMERICA: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 40 EUROPE: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 41 ASIA PACIFIC: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 105
7.5 RNA INTERFERENCE 106
7.5.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT ADOPTION OF TECHNIQUE FOR DIAGNOSTICS AND THERAPEUTICS 106
TABLE 42 RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 43 NORTH AMERICA: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 44 EUROPE: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 45 ASIA PACIFIC: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 108
8 RNA ANALYSIS MARKET, BY APPLICATION 109
8.1 INTRODUCTION 110
TABLE 46 RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
8.2 DRUG DISCOVERY 110
8.2.1 GROWING POPULARITY OF TARGETED SEQUENCING-BASED APPROACHES IN DRUG DISCOVERY TO BOOST MARKET 110
TABLE 47 RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 48 NORTH AMERICA: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 49 EUROPE: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 50 ASIA PACIFIC: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 113
8.3 CLINICAL DIAGNOSTICS 113
8.3.1 GROWING ADOPTION OF TRANSCRIPTOMICS FOR LARGE-SCALE GENE EXPRESSION PROFILING OF ONCOLOGICAL DISORDERS TO FUEL GROWTH 113
TABLE 51 RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 52 NORTH AMERICA: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 53 EUROPE: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 54 ASIA PACIFIC: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116
8.4 TOXICOGENOMICS 117
8.4.1 GROWING FOCUS ON ADR STUDIES TO DRIVE ADOPTION OF TRANSCRIPTOMICS FOR SYSTEMIC TOXICOLOGY 117
TABLE 55 RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 56 NORTH AMERICA: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 57 EUROPE: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 58 ASIA PACIFIC: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 119
8.5 COMPARATIVE TRANSCRIPTOMICS 120
8.5.1 WIDE ADOPTION OF TRANSCRIPTIONAL PROFILES TO STUDY EVOLUTION AMONG SPECIES TO PROPEL GROWTH 120
TABLE 59 RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 60 NORTH AMERICA: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 61 EUROPE: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 62 ASIA PACIFIC: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 122
9 RNA ANALYSIS MARKET, BY END USER 123
9.1 INTRODUCTION 124
TABLE 63 RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 124
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 124
9.2.1 INCREASING INVESTMENTS FOR ONCOLOGY THERAPEUTICS TO DRIVE USE OF OMICS TECHNOLOGIES IN PHARMA & BIOTECH COMPANIES 124
TABLE 64 RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 65 NORTH AMERICA: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 66 EUROPE: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 67 ASIA PACIFIC: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 127
9.3 HOSPITALS & DIAGNOSTIC CENTERS 127
9.3.1 USE OF WHOLE-BLOOD TRANSCRIPTOME PROFILES FOR DISEASE DIAGNOSTICS TO FAVOR MARKET GROWTH 127
TABLE 68 RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 69 NORTH AMERICA: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 70 EUROPE: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 71 ASIA PACIFIC: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 129
9.4 ACADEMIC & RESEARCH INSTITUTES 130
9.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH 130
TABLE 72 RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 73 NORTH AMERICA: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 74 EUROPE: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 75 ASIA PACIFIC: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 132
9.5 CONTRACT RESEARCH ORGANIZATIONS 132
9.5.1 GROWING OUTSOURCING OF SERVICES BY PHARMACEUTICAL COMPANIES FOR FASTER DRUG DISCOVERY TO AID MARKET GROWTH 132
TABLE 76 RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 77 NORTH AMERICA: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 78 EUROPE: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 79 ASIA PACIFIC: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134
10 RNA ANALYSIS MARKET, BY REGION 135
10.1 INTRODUCTION 136
TABLE 80 RNA ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 136
10.2 NORTH AMERICA 137
FIGURE 30 NORTH AMERICA: RNA ANALYSIS MARKET SNAPSHOT 138
TABLE 81 NORTH AMERICA: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028(USD MILLION) 139
TABLE 82 NORTH AMERICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
TABLE 83 NORTH AMERICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
TABLE 84 NORTH AMERICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
TABLE 85 NORTH AMERICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 141
10.2.1 US 141
10.2.1.1 US to dominate North American RNA analysis market during forecast period 141
TABLE 86 US: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142
TABLE 87 US: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 88 US: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 89 US: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.2.2 CANADA 144
10.2.2.1 Improving funding and infrastructure for omics-based research to support market growth 144
TABLE 90 CANADA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 91 CANADA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
TABLE 92 CANADA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 93 CANADA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 147
10.2.3 NORTH AMERICA: RECESSION IMPACT 147
10.3 EUROPE 147
TABLE 94 EUROPE: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 95 EUROPE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149
TABLE 96 EUROPE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149
TABLE 97 EUROPE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 98 EUROPE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 150
10.3.1 GERMANY 151
10.3.1.1 Germany to hold largest share of European RNA analysis market during forecast period 151
TABLE 99 GERMANY: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 152
TABLE 100 GERMANY: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 152
TABLE 101 GERMANY: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153
TABLE 102 GERMANY: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 153
10.3.2 UK 154
10.3.2.1 Rising public and private funding for research to drive market growth 154
TABLE 103 UK: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 154
TABLE 104 UK: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155
TABLE 105 UK: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 106 UK: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
10.3.3 FRANCE 156
10.3.3.1 Increasing government support for omics-based research to support market growth 156
TABLE 107 FRANCE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 157
TABLE 108 FRANCE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
TABLE 109 FRANCE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158
TABLE 110 FRANCE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 158
10.3.4 ITALY 159
10.3.4.1 Improving R&D expenditure and disease diagnostics to boost market 159
TABLE 111 ITALY: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 159
TABLE 112 ITALY: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160
TABLE 113 ITALY: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160
TABLE 114 ITALY: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 161
10.3.5 SPAIN 161
10.3.5.1 Increasing collaborations for enhancing research to support market growth 161
TABLE 115 SPAIN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162
TABLE 116 SPAIN: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 162
TABLE 117 SPAIN: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 163
TABLE 118 SPAIN: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 163
10.3.6 SWITZERLAND 164
10.3.6.1 Well-established pharmaceutical industry to drive market growth 164
TABLE 119 SWITZERLAND: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 164
TABLE 120 SWITZERLAND: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165
TABLE 121 SWITZERLAND: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 122 SWITZERLAND: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 166
10.3.7 REST OF EUROPE 166
TABLE 123 REST OF EUROPE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 167
TABLE 124 REST OF EUROPE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167
TABLE 125 REST OF EUROPE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168
TABLE 126 REST OF EUROPE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 168
10.4 EUROPE: RECESSION IMPACT 169
10.5 ASIA PACIFIC 169
FIGURE 31 ASIA PACIFIC: RNA ANALYSIS MARKET SNAPSHOT 170
TABLE 127 ASIA PACIFIC: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 128 ASIA PACIFIC: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171
TABLE 129 ASIA PACIFIC: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
TABLE 130 ASIA PACIFIC: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172
TABLE 131 ASIA PACIFIC: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 173
10.5.1 CHINA 173
10.5.1.1 China to be fastest-growing market in Asia Pacific during forecast period 173
TABLE 132 CHINA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174
TABLE 133 CHINA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175
TABLE 134 CHINA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 175
TABLE 135 CHINA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 176
10.5.2 JAPAN 176
10.5.2.1 Early adoption of technologically advanced products to drive market growth 176
TABLE 136 JAPAN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177
TABLE 137 JAPAN: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 177
TABLE 138 JAPAN: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178
TABLE 139 JAPAN: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 178
10.5.3 INDIA 179
10.5.3.1 Increasing pharmaceutical R&D spending and government funding for research to drive market growth 179
TABLE 140 INDIA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
TABLE 141 INDIA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180
TABLE 142 INDIA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 143 INDIA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 181
10.5.4 REST OF ASIA PACIFIC 182
TABLE 144 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 183
TABLE 145 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183
TABLE 146 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184
TABLE 147 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 184
10.6 ASIA PACIFIC: RECESSION IMPACT 185
10.7 LATIN AMERICA 185
10.7.1 GROWTH IN PHARMACEUTICAL INDUSTRY IN MEXICO TO SUPPORT MARKET GROWTH 185
TABLE 148 LATIN AMERICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 186
TABLE 149 LATIN AMERICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186
TABLE 150 LATIN AMERICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 151 LATIN AMERICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 187
10.8 LATIN AMERICA: RECESSION IMPACT 188
10.9 MIDDLE EAST & AFRICA 188
10.9.1 IMPROVING FOCUS ON PRECISION MEDICINE AND DISEASE GENETICS TO DRIVE MARKET GROWTH 188
TABLE 152 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 189
TABLE 153 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 189
TABLE 154 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 190
TABLE 155 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 190
10.10 MIDDLE EAST & AFRICA: RECESSION IMPACT 191
11 COMPETITIVE LANDSCAPE 192
11.1 INTRODUCTION 192
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 192
FIGURE 32 RNA ANALYSIS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 193
11.3 REVENUE SHARE ANALYSIS 194
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 194
11.4 MARKET SHARE ANALYSIS 194
FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 195
TABLE 156 RNA ANALYSIS MARKET: DEGREE OF COMPETITION 195
11.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS 196
FIGURE 35 RNA ANALYSIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 197
11.5.1 STARS 197
11.5.2 EMERGING LEADERS 197
11.5.3 PERVASIVE PLAYERS 198
11.5.4 PARTICIPANTS 198
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 198
11.6.1 COMPANY PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES) 198
TABLE 157 COMPANY PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN RNA ANALYSIS MARKET 198
11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 199
TABLE 158 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN RNA ANALYSIS MARKET 199
11.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 200
FIGURE 36 RNA ANALYSIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/ SMES, 2022 200
11.7.1 PROGRESSIVE COMPANIES 201
11.7.2 STARTING BLOCKS 201
11.7.3 RESPONSIVE COMPANIES 201
11.7.4 DYNAMIC COMPANIES 201
11.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 202
TABLE 159 RNA ANALYSIS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 202
TABLE 160 RNA ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 203
11.9 COMPETITIVE SCENARIO AND TRENDS 203
11.9.1 PRODUCT LAUNCHES 203
TABLE 161 RNA ANALYSIS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–JUNE 2023 203
11.9.2 DEALS 204
TABLE 162 RNA ANALYSIS MARKET: DEALS, JANUARY 2020–JUNE 2023 204
11.9.3 OTHER DEVELOPMENTS 205
TABLE 163 RNA ANALYSIS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JUNE 2023 205
12 COMPANY PROFILES 206
12.1 KEY PLAYERS 206
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 THERMO FISHER SCIENTIFIC INC. 206
TABLE 164 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 206
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 207
12.1.2 F. HOFFMANN-LA ROCHE LTD. 212
TABLE 165 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 212
FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 213
12.1.3 BIO-RAD LABORATORIES, INC. 216
TABLE 166 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 216
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 217
12.1.4 ILLUMINA, INC. 220
TABLE 167 ILLUMINA, INC.: COMPANY OVERVIEW 220
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 221
12.1.5 EUROFINS SCIENTIFIC 224
TABLE 168 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 224
FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 224
12.1.6 AGILENT TECHNOLOGIES, INC. 227
TABLE 169 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 227
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 228
12.1.7 CD GENOMICS 230
TABLE 170 CD GENOMICS: COMPANY OVERVIEW 230
12.1.8 PROMEGA CORPORATION 232
TABLE 171 PROMEGA CORPORATION: COMPANY OVERVIEW 232
12.1.9 QIAGEN N.V. 234
TABLE 172 QIAGEN N.V.: COMPANY OVERVIEW 234
FIGURE 43 QIAGEN N.V.: COMPANY SNAPSHOT (2022) 235
12.1.10 DANAHER CORPORATION 237
TABLE 173 DANAHER CORPORATION: COMPANY OVERVIEW 237
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 238
12.1.11 MERCK KGAA 240
TABLE 174 MERCK KGAA: BUSINESS OVERVIEW 240
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022) 241
12.1.12 STANDARD BIOTOOLS INC. (FLUIDIGM CORPORATION) 243
TABLE 175 STANDARD BIOTOOLS INC.: BUSINESS OVERVIEW 243
FIGURE 46 STANDARD BIOTOOLS INC.: COMPANY SNAPSHOT (2022) 243
12.1.13 SEQUENTIA BIOTECH SL 245
TABLE 176 SEQUENTIA BIOTECH SL: BUSINESS OVERVIEW 245
12.1.14 ACOBIOM 246
TABLE 177 ACOBIOM: BUSINESS OVERVIEW 246
12.1.15 GENXPRO GMBH 247
TABLE 178 GENXPRO GMBH: BUSINESS OVERVIEW 247
12.2 OTHER PLAYERS 248
12.2.1 LEXOGEN GMBH 248
12.2.2 CENIX BIOSCIENCE GMBH 249
12.2.3 TAKARA HOLDINGS INC. 250
12.2.4 BIOMÉRIEUX SA 251
12.2.5 LC SCIENCES LLC 252
12.2.6 OXFORD NANOPORE TECHNOLOGIES 253
12.2.7 ZYMO RESEARCH CORPORATION 254
12.2.8 GENEDX 255
12.2.9 PARTEK INCORPORATED 255
12.2.10 BGI GROUP 256
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 257
13.1 DISCUSSION GUIDE 257
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 260
13.3 CUSTOMIZATION OPTIONS 262
13.4 RELATED REPORTS 262
13.5 AUTHOR DETAILS 263
